The Journal of Allergy and Clinical Immunology
Volume 119, Issue 4 , Pages 937-943 , April 2007

Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1

  • Tamar Kinaciyan, MD

      Affiliations

    • From the Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases
    • ,
  • Beatrice Jahn-Schmid, PhD

      Affiliations

    • Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna
    • ,
  • Astrid Radakovics

      Affiliations

    • Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna
    • ,
  • Bettina Zwölfer

      Affiliations

    • Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna
    • ,
  • Claudia Schreiber, MD

      Affiliations

    • From the Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases
    • ,
  • James N. Francis, PhD

      Affiliations

    • Upper Respiratory Medicine, National Heart and Lung Institute, Imperial College, London
    • ,
  • Christof Ebner, MD

      Affiliations

    • Allergy Clinic Reumannplatz, Vienna
    • ,
  • Barbara Bohle, PhD

      Affiliations

    • Department of Pathophysiology, Center for Physiology and Pathophysiology, Medical University of Vienna
    • Corresponding Author InformationReprint requests: Barbara Bohle, PhD, Medical University of Vienna, Center for Physiology and Pathophysiology, Department of Pathophysiology, Waehringer Guertel 18-20, AKH-3Q, A-1090 Wien, Austria.

Received 17 August 2006 ,Revised 2 November 2006 ,Accepted 3 November 2006.

  • Image Result

    IgE-inhibition ELISA. Sera of 9 patients obtained before SLIT were preincubated with titrated concentrations of Bet v 1 (solid circles) or Mal d 1 (open circles). The mean value of inhibition of IgE b

    IgE-inhibition ELISA. Sera of 9 patients obtained before SLIT were preincubated with titrated concentrations of Bet v 1 (solid circles) or Mal d 1 (open circles). The mean value of inhibition of IgE binding to Bet v 1 (left) and Mal d 1 (right) is shown. ∗P < .05, Wilcoxon signed rank test.

  • Image Result
    Bet v 1–specific and Mal d 1–specific IgE and IgG4 levels during SLIT. Sera were tested for allergen-specific antibody levels before (t = 0) and after 1 year (t = 52) by ELISA. ∗P < .05, Wilcoxon sign

    Bet v 1–specific and Mal d 1–specific IgE and IgG4 levels during SLIT. Sera were tested for allergen-specific antibody levels before (t = 0) and after 1 year (t = 52) by ELISA. ∗P < .05, Wilcoxon signed rank test.

  • Image Result
    Bet v 1–induced and Mal d 1–induced proliferation during SLIT. PBMCs isolated before (t = 0) and after 1 year (t = 52) were stimulated with the concentration of allergens individually inducing the hig

    Bet v 1–induced and Mal d 1–induced proliferation during SLIT. PBMCs isolated before (t = 0) and after 1 year (t = 52) were stimulated with the concentration of allergens individually inducing the highest proliferation at t = 0. ∗P < .05, Wilcoxon signed rank test.

  • Image Result
    SLIT affects T cells specific for all Bet v 1 epitopes. Bet v 1–specific TCLs from 7 individuals were mapped with 12-mer peptides representing the entire aa sequence of Bet v 1 before (t = 0) and afte

    SLIT affects T cells specific for all Bet v 1 epitopes. Bet v 1–specific TCLs from 7 individuals were mapped with 12-mer peptides representing the entire aa sequence of Bet v 1 before (t = 0) and after 1 year (t = 52). Numbers indicate SI to individual peptides, and gray boxes mark positive responses (SI > 2). The aa sequences of fragments created by gastrointestinal digestion of Bet v 1 and their aa position are depicted. The arrow indicates the most relevant epitope for cross-reactivity with Mal d 1, Bet v 1142-153.27

 Supported by the Fonds zur Förderung der wissenschaftlichen Forschung (SFB-F1807-B04), Austria.Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(06)02355-4

doi: 10.1016/j.jaci.2006.11.010

The Journal of Allergy and Clinical Immunology
Volume 119, Issue 4 , Pages 937-943 , April 2007

Article Tools

* Image Usage & Resolution